Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluticasone Propionate MDPI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: Fp MDPI | EXPERIMENTAL | Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA) |
| Treatment B: FS MDPI | EXPERIMENTAL | Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA) |
| Treatment C: Comparator | ACTIVE_COMPARATOR | Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA) |
| Name | Type | Description |
|---|---|---|
| Fluticasone Propionate MDPI | DRUG | - |
| Fluticasone Propionate/Salmeterol MDPI | DRUG | - |
| Fluticasone propionate/salmeterol | DRUG | - |
Inclusion Criteria: * The patient is a male or female aged 4 through 11 years of age, inclusive * Severity of disease: The patient has persistent asthma * Asthma diagnosis: The patient has a diagnosis of asthma as defined by the NIH. * The patient has required less than 4 inhalations per week of re...
Fluticasone Propionate MDPI is an investigational small molecule being developed for the treatment of asthma. It is a metered dose inhaler formulation of fluticasone propionate, a corticosteroid. The drug is intended for use in patients with asthma, and it is currently in Phase 1 clinical development.
Fluticasone Propionate MDPI is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma.
Fluticasone Propionate MDPI is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial involving 20 patients with asthma.
Fluticasone Propionate MDPI has one completed clinical trial, identified as NCT02680561. This was a double-blind, active-controlled study comparing treatments in 4 to 11 year old patients with asthma. The trial was conducted in the United States and enrolled 20 participants.
Fluticasone Propionate MDPI is a specific formulation of fluticasone propionate, delivered via a metered dose inhaler. While the active ingredient is the same as other fluticasone propionate products, the MDPI designation refers to the specific device and formulation being developed by Teva.